Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2024-519578-38-00
Authorised, recruiting Phase III

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension

2024-519578-38-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Hormonal diseases
Decision date
09/12/2025
Enrollment target
61
Sites
Italy, Germany, France, Belgium, Netherlands, Poland

Condition studied

Classic congenital adrenal hyperplasia

Investigational medicinal product(s)

Atumelnant 40 mg tabletAtumelnant 80 mg tabletsAtumelnant 20 mg tabletsTablet

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Part A: -Incidence of TEAEs including treatment emergent SAEs and any Aes leading to discontinuation. -Change from baseline in morning A4 at Week 8 Part B: -Percent change from baseline in GC daily dose at Week 28 while serum early morning A4≤ULN Part C: -Change from baseline in morning A4 over time

Endpoint detail

Part A: -Change from baseline in morning serum 17-OHP at Week 8 -Plasma and blood concentrations of atumelnant, Part B: -Change from baseline in morning A4 at Week 4 -Change from baseline in morning 17 OHP at Week 4 -Proportion of participants with physiologic GC dose while serum early morning A4 <≤ULN at Week 28, Part C: -Change from baseline in morning 17-OHP over time -Percent change from baseline in GC daily dose over time -Proportion of participants with physiologic GC dose while serum early morning A4 <≤ULN over time -Percent change from baseline in GC daily dose (in hydrocortisone equivalents, mg/m2/day) while serum early morning (before 11:00) A4 ≤ULN over time.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-519578-38-00 on CTIS ↗ ← All trials in the EU